Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07845747
PHASE4

Comparison Between Efficacy of Inhaled VS Intravenous Tranexamic Acid for Hemoptysis

Sponsor: Dow University of Health Sciences

View on ClinicalTrials.gov

Summary

This will be a prospective comparative cohort study and will take place at the Ward II- Ojha Institute of Chest Diseases (OICD) ,Dow University of Health Sciences in Karachi. It will be conducted over six months after obtaining necessary approvals. We will recruit 154 patients aged 18-60 years, regardless of gender, who will present with complain of hemoptysis. Patients will be selected through a non-probability consecutive sampling method, where each eligible patient will be approached for participation. Participants will be randomly assigned to one of two groups using a lottery method: * Group A will receive 500 mg of inhaled Tranexamic acid three times a day. * Group B will receive 500 mg of intravenous Tranexamic acid three times a day. Once patients give consent for participation, we will gather detailed medical history. Blood tests and X-rays will be done to assess each patient's health status. We will then monitor the amount of blood expectorated after 30 minutes, 6 hours, 12 hours, and 24 hours post-administration. We will also observe any side effects from the treatment.

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

154

Start Date

2026-09-15

Completion Date

2027-02-15

Last Updated

2026-09-29

Healthy Volunteers

No

Conditions

Interventions

DRUG

Tranexamic Acid

Tranexamic acid 500 mg administered via inhaled route three times daily or intravenous route three times daily for management of hemoptysis

Locations (1)

Ward-2 Ojha Institute of Chest Diseases (OICD), Dow University of Health Sciences

Karachi, Sindh, Pakistan